The US PEPFAR initiative has brought HIV medication to millions of people globally. Behind this progress are the activists that pressured politicians and companies to put patients over patents.
Academic rigor, journalistic flair
Articles on Drug patents
Displaying all articles
The Medicines Patent Pool was created to promote public health, facilitating generic licensing for patented drugs that treat diseases predominantly affecting low- and middle-income countries.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Drug repurposing can redeem failed treatments and squeeze out new uses from others. But many pharmaceutical companies are hesitant to retool existing drugs without a high return on investment.
The path to using old drugs for COVID is full of potholes. So why are we using the same old flawed methods when we actually know what works?
The pharmaceutical industry overall has been deeply opposed to waiving COVID-19 vaccine patents, but a historian of the industry explains that drug companies once opposed patents altogether.
Lowering the tax rates on profits from patents registered in Australia is unlikely to increase local research and development. But it will be a gift for multinationals.
A transcript of The Conversation Weekly podcast episode #3.
Plus new research on why China is closing down coal-fired power stations. Listen to episode 3 of The Conversation Weekly.
The TRIPS waiver makes COVID-19 treatments more accessible globally by enabling manufacture and distribution of COVID-19 drugs and medical supplies that would normally be protected by patents.
Drug companies normally use patents to protect new treatments.
Presidential candidates and the current president have all talked about ways to lower drug costs, but experts know it is going to take more than politics to change how drugs are priced in the US.
Insurance companies sometimes try to cut costs by substituting less expensive drugs for a specific drug prescription. That’s raising problems in many cases, and actually causing harm.
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
Pharmaceutical companies focus on small molecules they’ve devised – and can easily patent. But nature’s already come up with many antibacterial compounds that drug designers could use to make medicines.
The number of people dying from opioid overdose continues to rise, in part because of cheap street drugs. Yet the price of a drug used to treat addiction is out of reach for many.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Top contributors
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Associate Professor, Newcastle Business School, University of Newcastle
-
Part-time lecturer at the Global Health & Social Medicine, Harvard University, and Lecturer at the School of Public Health, College of Health Sciences, University of Liberia
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Reader in Intellectual Property Law, City, University of London
-
Vice Provost for Faculty Affairs and Asa Griggs Candler Professor of Law, Emory University
-
Professor of Intellectual Property, University of California College of the Law, San Francisco
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
Professor, Abell Chair in Synthetic Biology, Colorado State University
-
Virology Research Scientist, University of Washington
-
Postdoctoral Researcher in Chemical and Biological Engineering, Colorado State University
-
Associate Professor of History and Social Medicine, Florida State University
-
Associate Professor of Health Behavior & Health Education, University of Michigan
-
Lecturer in Economics, Monash University
-
Associate Professor & Program Director, Public Health Policy & Management, University of Arizona
